INDEX

5-hydroxytryptophan, and neuroendocrine responses in SAD patients, 46

Alcoholism, and light therapy, 78
Alzheimer’s disease, and light therapy, 78, 79
American Sleep Disorders Association, 78
Anorexia nervosa
See Eating disorders
Antidepressants
See Medication treatment, of SAD
Anxiety disorder
See Panic disorder
Asia
prevalence of SAD, 37, 41
research studies on SAD, 26, 27
Atenolol, as treatment for SAD, 43, 93
Australia, genetic studies in incidence of SAD, 48

B12, as treatment for SAD, 93
BDI
See Beck Depression Inventory (BDI)
Beck Depression Inventory (BDI)
and diagnosis of SAD, 28, 32
and measurement of treatment effectiveness, 108
Bipolar disorders
among SAD patients, 27, 33, 34-5, 36

and side effects of light therapy, 73

Bulimia nervosa
See Eating disorders
Bupropion, in treatment of SAD, 91

Canadian Consensus Group on seasonal affective disorder (SAD), 17, 18
Canadian Journal of Diagnosis, 19
Canadian Psychiatric Association, 18
Canadian Standards Association, 72
Carbohydrates
craving for, in SAD patients, 23, 31, 71
and serotonin synthesis, 46
See also Eating disorders
Catecholamine, depletion in SAD patients in remission with light therapy, 47
Children
and light therapy, 76-7
with SAD, 44
Chronic fatigue syndrome,
comorbidity with SAD, 106
CIDI (Composite International Diagnostic Interview), 38
Circadian rhythms
disorders, and light therapy, 64, 67, 68, 78-9
role in SAD, 43-5, 51
Clarke Institute of Psychiatry (Toronto), 17
Cocaine abuse, comorbidity with SAD, 106
Cochrane Collaboration study, 65
Cognitive-behavioural therapy (CBT), for SAD, 107-8
Composite International Diagnostic Interview (CIDI), 38
Concentration, inability for, 24

D-fenfluramine
medication, as treatment for SAD, 93
and serotonin transmission, 46
Dawn simulation technique, 66-7
Dementia, and light therapy, 78, 79
Depression
atypical, compared with SAD, 33-4
nonseasonal, and light therapy, 77-8, 79
nonseasonal, compared with SAD, 24, 25, 28
severity, and choice of treatment, 96-8
treatment resistant, 108-11
vegetative symptoms, 23, 25
See also Light therapy; Medication treatment, of SAD; SAD (seasonal affective disorder)
Depressive Experiences Questionnaire, 50
Dexamethasone, and cortisol suppression in SAD patients, 48
D,L-fenfluramine, and neuroendocrine responses in SAD patients, 46
Dopamine, possible role in SAD, 47, 51
DSM-III-R
diagnostic criteria for SAD, 20, 21, 22, 23, 38-9
personality disorders in SAD patients, and light therapy treatment outcome, 71
DSM-IV, diagnostic criteria for SAD, 21, 23, 24, 33

Eating disorders
appetite, increase in SAD patients, 23, 31, 33
cognitive therapy for, 107
comorbidity with SAD, 104, 105, 106, 107
and light therapy, 78
seasonal pattern, 35
See also Carbohydrates
Elderly
effect of light therapy on eyes, 75
and insomnia, treatment with light therapy, 79
and SAD, 40, 41
Europe
prevalence of SAD, 37, 41
research studies on SAD, 26
Eyes
eyeblink, reduced in SAD patients, 47
as receptors of light therapy, 68
retina, role in SAD, 45, 51
risk factors and light therapy, 73-5, 76

Fatigue, in SAD patients, 48, 106
Female-to-male ratio, of people with SAD, 39, 41
Fenfluramine
d-fenfluramine, medication, as treatment for SAD, 93
d-fenfluramine, and serotonin transmission, 46
d,l-fenfluramine, and neuroendocrine responses in SAD patients, 46
Fluorescent light box
availability, 72
use in treatment of SAD, 64, 65-6, 67, 68, 69, 70, 76
Fluoxetine, use in treatment of SAD, 89-90, 92, 96, 98, 101
Freiburg Personality Inventory, 50

Genetic factors, in SAD, 47-8, 51
Giessen Test, 50
Global seasonality score (GSS), 28, 30, 31, 48
GSS (global seasonality score), 28, 30, 31
Guilt, feelings of, 24

**Hamilton Depression Rating Scale (HDRS)**
and diagnosis of SAD, 28, 31-2
SIGH-SAD (Interview Guide), 32
and measurement of treatment effectiveness, 108

**HDRS**
See Hamilton Depression Rating Scale (HDRS)

Health and Welfare Canada, 17

**HIGH-SAD (Hypomania Interview Guide for Seasonal Affective Disorder),** 35

Hormonal changes, in SAD patients, 48-9

**Hypericum**
as treatment for SAD, 75, 93, 94

**Hypersomnia, and SAD,** 23, 24, 31, 33, 71

**Hypomania**
diagnostic instruments for, 34-5
Interview Guide for Seasonal Affective Disorder (HIGH-SAD), 35
side effect of light therapy, 73, 74

Hypothalamic-pituitary-adrenal (HPA) overactivity, in SAD patients, 48

**ICD-IO, diagnostic criteria for SAD,** 21

Iceland, lower SAD incidence compared with Americans, 48

Insomnia, and SAD, 24

Internet sites, on SAD, 19

**Interpersonal psychotherapy (IPT),** for SAD, 107-8

**Inventory of Seasonal Variation (ISV),** 31

**ISV**
See Inventory of Seasonal Variation (ISV)

**Jet lag, and light therapy,** 78, 79
*Journal of Biological Rhythms,* 78-9

**L-tryptophan**
medication, as treatment for SAD, 93, 94, 110, 111
and serotonin transmission, 46

Latitude, and prevalence estimate of SAD, 40, 41

**LED light cap,** 66

**Levodopa, as treatment for SAD,** 93

Light
cognitive sensitivity to, in SAD patients, 49-50
photoperiod decrease, and risk of SAD onset, 41, 51

Light therapy
definition, 64
devices, 64, 65-7, 72, 76
discontinuation of, 102, 104, 110
duration of exposure, 64, 65, 67, 68-9
intensity, 64, 65, 67, 68-9, 76, 81, 90, 93, 109
lights, incandescent versus halogen, 74, 76
melatonin rhythms, phase advance of, 43
parameters, 67-8
photoreceptors, 45
placebo condition, appropriate, 80-1
positioning, and light source, 69, 76
response to, 33, 71, 109-10
reversal of, and neurotransmitter depletion, 47
risk factors, 73, 74, 75, 76
side effects, 73-5, 76, 98
during summer, 102-3, 104
timing, 44, 64, 67, 68, 69-70, 72, 76, 109
treatment decisions, 96-8
and medication, 75, 90, 99-101, 110, 111
for other disorders, 78-9, 107
outcome predictors, 71
practical tips for, 72-3
trial length, 71, 76, 101
and tryptophan, effect reversal by
deletion of, 46
wavelength, 67, 70, 73, 76
Light visor, 66
Longitudinal studies, of SAD patients
American (Leonhardt et al.,
Schwartz et al.), 26
British (Thompson et al.), 26
for identification of patients with
bipolar disorders, 35
Japanese (Sakamoto et al., Sugishita
et al.), 26, 27
Swiss (Graw et al.), 26
M-chlorophenylpiperazine, and
neuroendocrine responses in SAD
patients, 46
Medical Research Council of Canada, 17
Medication treatment, of SAD
combined with light therapy, 99-101
dosage, 91-2
side effects, 92
treatment decisions, 96-8
treatment trial length, 101
using
atenolol, 93
B12, 93
bupropion, 91
d-fenfluramine, 93
fluoxetine, 89-90, 92, 96, 98, 101
l-tryptophan, 93, 94, 110, 111
levodopa, 93
melatonin, 93, 94
moclobemide, 90-1
propranolol, 93
sertraline, 89, 90, 91-2, 101
tranlynclypromine, 91
Melatonin
medication, as treatment for SAD, 93, 94
role in SAD, 42-3, 51
suppression in light therapy, 64
Metabolic changes, in SAD patients,
48-9
Moclobemide, use in treatment of
SAD, 90-1
Mood reactivity, in SAD patients, 24,
33
National Comorbidity Survey (US),
38-9
National Institute of Mental Health
(NIMH), 13, 14, 26
Neuroticism, in SAD patients, 50
Neurotransmitters, role in SAD
dopamine, 47, 51
noradrenaline, 47, 51
serotonin, 14, 46
Noradrenaline, possible role in SAD,
47, 51
North America
higher incidence of SAD, compared
with Icelanders, 48
prevalence of SAD, 37, 41
research studies on SAD, 26
Obsessive-compulsive disorder
comorbidity with SAD, 104, 105,
106
and light therapy, 78
Panic disorder
cognitive therapy for, 107
comorbidity with SAD, 104, 105,
106, 107
and light therapy, 78, 79
seasonal influence on, 35
Personality disorders
comorbidity with SAD, 50, 51, 71,
105-6, 107
and light therapy, 78
Pharmacological agents
See Medication treatment, of SAD;
names of specific drugs
“Phase shifting,” treatment for SAD,
44
Phototherapy
See Light Therapy
Placebo condition, for light treat-
ment studies, 80-1
Posttraumatic stress disorder, and SAD, 35
Premenopausal women, and SAD, 47
Premenstrual syndrome
comorbidity with SAD, 35, 105, 107
and light therapy, 78, 79
Prolactin, possible role in SAD, 47
Propranolol, as treatment for SAD, 43, 93
Psychological factors, in SAD patients, 49-50, 104-7
Psychomotor impairment, in SAD patients
agitation, 24
retardation/paralysis, 24, 33
Psychotherapy, as treatment for SAD, 107-8, 111

RDC (See Research Diagnostic Criteria), 34-5
Remission
following treatment, 27
seasonal, 22-3
Research Diagnostic Criteria (RDC), 34-5
Retina, of SAD patients, 45
Reverse vegetative symptoms, 23, 25, 33, 34
Rosenthal, N.E.
diagnostic criteria for SAD, 21
light therapy as treatment for SAD, 14, 65

S-SAD (subsyndromal seasonal affective disorder)
characteristics, 30
and light therapy, 77-8, 79
SAD (seasonal affective disorder)
and circadian rhythms, 43-5, 51
compared with nonseasonal depression, 25, 28, 33-5
consensus guidelines project, 17-9
demographic variables, 39, 40, 41
diagnosis stability, 25-8
diagnostic criteria
DSM-III-R, 20, 21, 22, 23
DSM-IV, 20, 23, 24, 33, 36
ICD-IO, 21
Rosenthal, 21
diagnostic instruments
Beck Depression Inventory (BDI), 28, 32
Hamilton Rating Scale for Depression (HRSD), 28, 31-2
Inventory of Seasonal Variation (ISV), 31
Seasonal Pattern Assessment Questionnaire (SPAQ), 28-31, 36
duration, 20-2
epidemiology, 36-41
etiology, 41-8
and eyes, role of, 45, 47, 51
genetic factors, 47-8, 51
historical references, 13
hormonal changes, 48-9
and latitude, effect of, 40, 41
and melatonin, role of, 42-3, 51
metabolic changes, 49
and neurotransmitters, role in, 46-7, 51
onset, 20-2
pathophysiology, 48-51
personality factors, 50, 51, 71
photoperiod decrease, and risk of onset, 41, 51
prevalence of, 36-41
psychological factors, 49-50
remission
following treatment, 27
seasonal, 22-3
research studies, 17-9, 25-8
screening for, 31, 37
and sex of patients, 39, 41
and thermoregulatory heat loss, 47
treatment
antidepressant medication, 43, 89-94, 96-101, 110, 111
commencement of, 103-4
comorbid psychiatric disorders, 104-7
duration, 101-3, 104
high-density negative ions, 79, 80
light therapy, 15, 33, 43, 64-79, 96-101
limited response to, 108-11
psychotherapy, 107-8
relapse after discontinuation of, 101-2
resistance to, 108-11
sleep deprivation, 80
walking exercise, 80, 107
See also Depression; Light therapy;
Medication treatment, of SAD; S-SAD (subsyndromal seasonal affective disorder)
Seasonal Pattern Assessment Questionnaire (SPAQ)
and genetic studies of SAD, 48
and determination of prevalence of SAD, 36-8
and diagnosis of SAD, 28-31
limitations of, 37-8
as screening instrument for SAD, 31, 37
Serotonin, role in SAD, 14, 46
Sertraline, use in treatment of SAD, 89, 90, 91-2, 101
Sex, of patients with SAD, 39
Shift work, and light therapy, 78, 79
SIGH-SAD instrument
See Hamilton Depression Rating Scale (HDRS)
Sleep
See Hypersomnia; Insomnia
Society for Light Treatment and Biological Rhythms, 18, 78
formation of, 14
Society for Research in Biological Rhythms, 18
SPAQ
See Seasonal Pattern Assessment Questionnaire (SPAQ)
St. John’s Wort, as treatment for SAD, 75, 93, 94
Subsyndromal seasonal affective disorder
See S-SAD (subsyndromal seasonal affective disorder)
Suicidal ideation, 24
Sumatriptan, and neuroendocrine responses in SAD patients, 46
Summer remission, of depressive symptoms in SAD patients, 22-3
Tanning salons, 73
Thermoregulatory heat loss, in SAD patients, 47
Thyroid function, in SAD patients, 49, 51
Tranylcypromine, use in treatment of SAD, 91
Tryptophan depletion in SAD patients in remission with light therapy, 47
and serotonin transmission, 46
US National Comorbidity Survey, 38-9
US Underwriters Laboratory, 72
Vegetative symptoms, reverse, 23, 25, 33, 34
Vitamin abnormalities, in SAD patients, 49
Von Zerssen depression rating scale, 26
Weight
gain, 23, 24, 31, 33, 71
loss, 24
Women as majority of SAD patients, 39, 41
premenopausal, and SAD, 47
premenstrual syndrome, and SAD, 35